[CAS NO. 476181-74-5] Golimumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [476181-74-5]

Catalog

HY-P99111

Brand

MCE

CAS

476181-74-5

DESCRIPTION [476181-74-5]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Golimumab]

For research use only. We do not sell to patients.

Summary

Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis . Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research ^[1] ^[2] ^[3] .

IC50 & Target

CD40

In Vitro

Golimumab (CNTO-148) (0.1-10 μg /mL; 24-72 hours; transmembrane TNFα–transfected Jurkat cells) induces reductions in the viability of transmembrane TNFα–expressing cells ^[1] .
Golimumab (CNTO-148) (10 μg /mL; 48 hours; transmembrane TNFα–transfected Jurkat cells) induces apoptosis, increase the levels of active caspase-3 and induces apoptotic DNA fragmentation ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1]

Cell Line:	Transmembrane TNFα–transfected Jurkat cells
Concentration:	0.1, 1 and 10 μg/mL
Incubation Time:	24, 48 and 72 hours
Result:	Reduced cell viability in a dose- and time-dependent manner.

Apoptosis Analysis ^[1]

Cell Line:	Transmembrane TNFα–transfected Jurkat cells
Concentration:	10 μg /mL
Incubation Time:	48 hours
Result:	Had the percentage of apoptotic cells for 30.29%.

Western Blot Analysis ^[1]

Cell Line:	Transmembrane TNFα–transfected Jurkat cells
Concentration:	10 μg /mL
Incubation Time:	48 hours
Result:	Increased the levels of active caspase-3 and induces apoptotic DNA fragmentation.

In Vivo

Golimumab (CNTO-148) (24 mg/kg; i.h.; daily, for 7 days; swiss-albino healthy male mice) inhibits oxidative stress, apoptotic cell death inflammatory response, thus improving renal function. Golimumab reduces all markers of kidney injury and attenuates cell death ^[2] .
Golimumab (CNTO-148) (1-10 mg/kg; i.p.;daily; for 4 weeks; Tg197 transgenic mouse model) relieves TNFα-induced arthritis in a mouse model of human ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss-albino healthy male mice ^[2]
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Reduced serum parameters like BUN, NGAL creatinine, cystatin C, and urinary parameters like KIM-1, NAG, albumin clusterin.

Animal Model:	Swiss-albino healthy male mice ^[2]
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Inhibited oxidative stress, reduces MDA concentrations and increases the GSH and catalase levels.

Animal Model:	Swiss-albino healthy male mice ^[2]
Dosage:	24 mg/kg
Administration:	Subcutaneous injection; daily, for 7 days
Result:	Inhibitd cisplatin-induced inflammation, decreased TNF-α, including IL-6, IL-1β, MCP-1, ICAM-1, and TGF-β1 levels and increases IL-10 concentrations, reduced caspase 3 in cisplatin injected mice kidneys.

Animal Model:	Tg197 transgenic mouse model ^[3]
Dosage:	1 and 10 mg/kg
Administration:	Intraperitoneal injection;for 4 weeks
Result:	Reduced the arthritic index.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00973479	Centocor, Inc.\|Schering-Plough	Arthritis, Rheumatoid	September 2009	Phase 3
NCT03100253	Mario Negri Institute for Pharmacological Research	Rheumatoid Arthritis	March 1, 2018	Phase 4
NCT04610476	University of Erlangen-Nürnberg Medical School	Psoriatic Arthritis\|Withdrawal\|Reduction	October 19, 2020	Phase 3
NCT04200833	Medical University of Graz	JIA Associated Uveitis	March 1, 2010
NCT00771251	Janssen Pharmaceutical K.K.\|Mitsubishi Tanabe Pharma Corporation	Rheumatoid Arthritis	May 2008	Phase 3
NCT02181673	Janssen Research & Development, LLC	Arthritis, Psoriatic	September 8, 2014	Phase 3
NCT00207740	Centocor, Inc.\|Centocor BV	Asthma	August 2004	Phase 2
NCT04108468	The Leeds Teaching Hospitals NHS Trust\|Janssen Pharmaceutica N.V., Belgium	Psoriatic Arthritis	October 27, 2015	Phase 3
NCT02186873	Janssen Research & Development, LLC	Ankylosing Spondylitis	September 3, 2014	Phase 3
NCT01863771	Janssen Pharmaceutical K.K.	Colitis, Ulcerative	March 15, 2013	Phase 3
NCT00727987	Janssen Pharmaceutical K.K.\|Mitsubishi Tanabe Pharma Corporation	Rheumatoid Arthritis	May 2008	Phase 3
NCT02728934	Janssen Scientific Affairs, LLC	Arthritis, Rheumatoid	February 25, 2016
NCT01081717	Janssen Biotech, Inc.	Rheumatoid Arthritis\|Arthritis, Psoriatic\|Ankylosing Spondylitis	April 14, 2009
NCT02687724	University College Dublin	Colitis	June 2016	Phase 4
NCT00487539	Janssen Research & Development, LLC\|Merck Sharp & Dohme LLC	Colitis, Ulcerative	August 2007	Phase 2\|Phase 3
NCT05071664	Janssen Research & Development, LLC	Arthritis, Psoriatic	October 25, 2021	Phase 2
NCT00975130	Merck Sharp & Dohme LLC	Arthritis, Rheumatoid	September 2009	Phase 3
NCT05405465	University of Zurich\|Merck Sharp & Dohme LLC	Ulcerative Colitis\|Flare Up, Symptom	January 1, 2018
NCT03182166	Centre Hospitalier Universitaire de Saint Etienne\|Merck Sharp & Dohme LLC	Ulcerative Colitis	November 21, 2017	Phase 2
NCT02438787	Janssen Research & Development, LLC	Axial Spondyloarthritis	July 31, 2015	Phase 3
NCT05242484	Janssen Research & Development, LLC	Colitis, Ulcerative	September 19, 2022	Phase 2
NCT04729296	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|University of South Florida	Diabetes Mellitus, Type 1	July 1, 2021	Phase 2
NCT00299546	Centocor, Inc.\|Schering-Plough	Arthritis, Rheumatoid	February 2006	Phase 3
NCT04725422	Seattle Children´s Hospital\|Boston Children´s Hospital, Boston, MA, USA\|Hospital for Special Surgery, New York City, NY, USA\|Joseph M Sanzari Children´s Hospital, Hackensack University Medical Center, Hackensack, NJ, USA\|Riley Children´s Hospital, Indianapolis, IN, USA\|University of North Carolina, Chapel Hill, NC, USA\|Royal Children´s Hospital, Melbourne, Australia\|Hacettepe University, Ankara, Turkey\|Bambino Gesù Children´s Hospital, Rome, Italy\|University of British Columbia, Vancouver, BC, Canada\|Meyer Children´s Hospital, Florence, Italy\|Mansoura University	Chronic Nonbacterial Osteomyelitis\|Chronic Recurrent Multifocal Osteomyelitis	August 1, 2018
NCT03124121	Guy´s and St Thomas´ NHS Foundation Trust\|Merck Sharp & Dohme LLC	Ulcerative Colitis	September 5, 2017	Phase 4
NCT02412085	Istituto Clinico Humanitas	Colitis, Ulcerative	March 2015	Phase 4
NCT02318667	Merck Sharp & Dohme LLC	Colitis, Ulcerative	February 27, 2015	Phase 4
NCT03885713	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Inflammatory Bowel Diseases\|Crohn Disease\|Ulcerative Colitis	September 10, 2019	Phase 4
NCT03557853	MSD Pharmaceuticals LLC	Ankylosing Spondylitis\|Coxitis	June 2016
NCT04156984	David Drobne\|University Medical Centre Ljubljana	Ulcerative Colitis	May 2020	Phase 4
NCT02390700	Janssen Inc.	Rheumatoid Arthritis	February 2015
NCT01288157	Centocor, Inc.	Healthy Adult Chinese Males	September 2010	Phase 1
NCT00265096	Centocor, Inc.\|Schering-Plough	Arthritis, Psoriatic	December 2005	Phase 3
NCT03729349	Janssen Inc.	Arthritis, Rheumatoid	January 15, 2019
NCT03733925	Johnson & Johnson Private Limited	Spondylitis, Ankylosing\|Arthritis, Psoriatic	January 7, 2019	Phase 4
NCT00264550	Centocor, Inc.\|Schering-Plough	Rheumatoid Arthritis	December 2005	Phase 3
NCT01248793	Centocor, Inc.	Ankylosing Spondylitis	October 2010	Phase 3
NCT01715896	MedImmune LLC	Rheumatoid Arthritis	March 2013	Phase 2
NCT01426815	University Hospital, Ghent\|Janssen Biologics B.V.	Peripheral Spondylarthritis	March 13, 2012	Phase 3
NCT01610947	University Hospital, Montpellier	Spondyloarthritis	May 14, 2012	Not Applicable
NCT02841176	Imperial College Healthcare NHS Trust\|Merck Sharp & Dohme LLC\|Imperial College London	Psoriatic Arthritis	July 2016	Not Applicable
NCT01804166	Janssen Scientific Affairs, LLC	Hepatosplenic T-Cell Lymphoma	March 21, 2013	Phase 4
NCT03016260	TcLand Expression S.A.\|European Commission	RheumatoId Arthritis	December 2016
NCT03662542	Janssen Research & Development, LLC	Colitis, Ulcerative	November 20, 2018	Phase 2
NCT03596645	Janssen Research & Development, LLC	Colitis, Ulcerative	October 29, 2018	Phase 3
NCT01668004	Merck Sharp & Dohme LLC	Ankylosing Spondylitis	September 3, 2012	Phase 4
NCT00955279	Centocor, Inc.	Sarcoidosis	November 2009	Phase 2
NCT02155335	Merck Sharp & Dohme LLC	Ulcerative Colitis	July 1, 2014	Phase 4
NCT05313620	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Ulcerative Colitis\|Thromboembolism	April 1, 2022	Phase 4
NCT03669029	Hospital de Manises\|General University Hospital of Valencia\|Hospital Clínico Universitario de Valencia\|Hospital de Sagunto\|Hospital Universitario La Fe\|Hospital General Universitario de Alicante\|Hospital Universitario Doctor Peset\|Hospital Arnau de Vilanova\|Hospital Provincial de Castellon\|Merck Sharp & Dohme LLC	Colitis, Ulcerative	October 1, 2018	Phase 4
NCT04218565	Wenjie Zheng\|Peking Union Medical College Hospital	Behcet Syndrome\|Uveitis	February 15, 2020	Phase 2
NCT03270501	University Ghent\|Merck Sharp & Dohme LLC\|the Flanders Institute for Biotechnology	Axial Spondyloarthritis	November 8, 2017	Phase 3
NCT05164198	Hanyang University Seoul Hospital\|Linical Korea	Ankylosing Spondylitis\|Axial Spondyloarthritis	January 15, 2022	Phase 4
NCT03253796	Merck Sharp & Dohme LLC	Spondyloarthritis	November 7, 2017	Phase 4
NCT04531423	Shanghai Mental Health Center	Major Depressive Disorder	October 1, 2020	Not Applicable
NCT02186886	Kliniken im Naturpark Altmuehltal	Ulcerative Colitis	June 2014	Phase 4
NCT03414502	University of Nebraska	Rheumatoid Arthritis	August 2007	Phase 3
NCT02758782	Charite University, Berlin, Germany	Ankylosing Spondylitis	September 2016	Phase 4
NCT01453725	Merck Sharp & Dohme LLC\|Johnson & Johnson	Spondylitis, Ankylosing	February 13, 2012	Phase 3
NCT04188249	Peking Union Medical College Hospital	Arthritis, Rheumatoid	July 1, 2019
NCT02425865	Groupe d´Etude Therapeutique des Affections Inflammatoires Digestives	ULCERATIVE COLITIS	December 2016	Phase 4
NCT02846545	Janssen Research & Development, LLC	Diabetes Mellitus, Type 1	August 26, 2016	Phase 2
NCT01217814	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	November 2010	Phase 2
NCT01900574	Janssen Research & Development, LLC	Colitis, Ulcerative	August 9, 2013	Phase 1
NCT03394586	University of Zurich	Ulcerative Colitis\|Flare Up, Symptom	January 1, 2018
NCT01248780	Centocor, Inc.\|Schering-Plough	Rheumatoid Arthritis	September 2010	Phase 3
NCT00265083	Centocor, Inc.\|Schering-Plough	Spondylitis, Ankylosing	December 2005	Phase 3
NCT03632759	Carla Greenbaum, MD\|Juvenile Diabetes Research Foundation\|Benaroya Research Institute	Type 1 Diabetes Mellitus	August 15, 2018	Early Phase 1
NCT02092285	Merck Sharp & Dohme LLC	Ulcerative Colitis	May 9, 2014	Phase 4
NCT01362153	Centocor, Inc.	Rheumatoid Arthritis	December 26, 2007	Phase 1
NCT00361335	Centocor, Inc.\|Schering-Plough	Rheumatoid Arthritis	September 2006	Phase 3
NCT02277444	Janssen Research & Development, LLC	Arthritis, Juvenile	December 17, 2014	Phase 3
NCT02437162	Janssen Research & Development, LLC	Axial Spondyloarthritis	September 3, 2015	Phase 3
NCT03298542	Janssen Research & Development, LLC	Pre-Symptomatic Type 1 Diabetes	October 16, 2017	Phase 1
NCT03773445	Hospital San Carlos, Madrid\|Hospital Universitario La Fe\|Hospital Universitario 12 de Octubre\|Hospital Universitario Ramon y Cajal\|Gregorio Marañón Hospital\|Complejo Hospitalario de Navarra\|Hospital Universitario Fundación Alcorcón\|Hospital Infanta Sofia\|Hospital Clínico Universitario de Valencia\|Puerta de Hierro University Hospital\|Hospital Universitario La Paz\|Hospital Universitario de Fuenlabrada\|Merck Sharp & Dohme LLC	Ulcerative Colitis	March 1, 2019
NCT03018925	Institut d´Investigació Biomèdica de Girona Dr. Josep Trueta	Ulcerative Colitis	October 2016
NCT01258777	Centocor, Inc.	Healthy Volunteers	October 2010	Phase 1
NCT03945903	Janssen Research & Development, LLC	Diabetes Mellitus, Type 1
NCT00488774	Janssen Research & Development, LLC\|Merck Sharp & Dohme LLC	Colitis, Ulcerative	August 2007	Phase 2\|Phase 3
NCT01871649	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Psoriatic Arthritis	August 2013	Phase 3
NCT01004432	Janssen Biotech, Inc.\|Merck Sharp & Dohme LLC	Arthritis\|Arthritis, Rheumatoid\|Autoimmune Diseases	December 2009	Phase 3
NCT02414984	Janssen-Cilag, S.A.	Rheumatoid Arthritis	March 2015
NCT00264537	Centocor, Inc.\|Schering-Plough	Rheumatoid Arthritis	December 2005	Phase 3
NCT00488631	Janssen Research & Development, LLC\|Merck Sharp & Dohme LLC	Colitis, Ulcerative	September 2007	Phase 3
NCT01295151	Julia Brown\|University of Leeds	Rheumatoid Arthritis	August 2011	Phase 4
NCT00207714	Centocor, Inc.\|Centocor BV	Rheumatoid Arthritis	November 2003	Phase 2
NCT02065713	Instituto de Medicina Molecular João Lobo Antunes\|Merck Sharp & Dohme LLC	Psoriatic Arthritis	August 2014	Phase 3
NCT01962974	Janssen Biotech, Inc.	Arthritis, Rheumatoid	October 2013	Phase 3
NCT01230827	Janssen Research & Development, LLC\|Schering-Plough	Juvenile Idiopathic Arthritis	December 2010	Phase 3
NCT03955861	Belfast Health and Social Care Trust\|British Medical Association\|Psoriasis and Psoriatic Arthritis Alliance\|Queen´s University, Belfast	Psoriatic Arthritis\|Psoriasis\|Enthesitis	February 14, 2019
NCT01718951	Tuen Mun Hospital	Spondyloarthropathy	August 2012	Phase 4
NCT01526174	House Research Institute\|Janssen Services, LLC	Autoimmune Inner Ear Disease	March 2012	Phase 1\|Phase 2
NCT05242471	Janssen Research & Development, LLC	Crohn´s Disease	July 22, 2022	Phase 2
NCT01988961	Janssen Research & Development, LLC	Colitis, Ulcerative	December 2013	Phase 2
NCT00675649	Centocor, Inc.	Asthma	May 2008	Phase 2

Appearance

Liquid

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.